Tumor necrosis factor-α and transforming growth factor-β reflect severity of liver damage in primary biliary cirrhosis
| Autor: | Keith D. Lindor, Paul Angulo, Gady G Katz, Julia Haber, Izabella M. Malkiewicz, Roberta A. Jorgensen, Neil H. Shear, E. Rolland Dickson, Manuela G. Neuman |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Male Cholagogues and Choleretics medicine.medical_specialty Biopsy Biliary cirrhosis medicine.medical_treatment Cholangitis Sclerosing Placebo Gastroenterology Primary biliary cirrhosis Double-Blind Method Transforming Growth Factor beta Fibrosis Internal medicine Immunopathology Humans Medicine Liver Diseases Alcoholic Chemotherapy Hepatology Liver Cirrhosis Biliary Tumor Necrosis Factor-alpha business.industry Ursodeoxycholic Acid Middle Aged medicine.disease Hepatitis C Ursodeoxycholic acid Endocrinology Cytokine Liver Female business Biomarkers medicine.drug |
| Zdroj: | Journal of Gastroenterology and Hepatology. 17:196-202 |
| ISSN: | 1440-1746 0815-9319 |
| DOI: | 10.1046/j.1440-1746.2002.02672.x |
| Popis: | BACKGROUND AND AIMS The pathogenesis of primary biliary cirrhosis (PBC) is unknown. The role of cytokines such as tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta (TGF-beta), and the effect of ursodeoxycholic acid (UDCA) in modifying the cytokine environment in patients with PBC has remained largely unstudied. Our aims were to determine: (i) the relationship between serum levels of TNF-alpha and TGF-beta and the severity of PBC; and (ii) the effects of UDCA therapy on TNF-alpha and TGF-beta levels in patients with PBC. METHODS We studied 90 patients who had been treated with UDCA (53 patients) or placebo (37 patients) for 2 years as part of a randomized, double-blind, controlled trial. Patients were divided into histological stage I/II or stage III/IV disease. Serum TNF-alpha and TGF-beta levels were quantified by enzyme-linked immunoabsorbent assay. RESULTS Baseline levels of TNF-alpha were significantly greater in patients with stage III/IV compared to stage I/II disease. After 2 years of treatment with UDCA, patients showed a significantly greater decrease in TNF-alpha levels and progression risk score compared to placebo-treated patients. TNF-alpha and TGF-beta levels were significantly reduced compared to baseline levels in the UDCA-treated group after 2 years, while there was no significant change in the levels of placebo-treated patients. CONCLUSIONS Serum TNF-alpha and TGF-beta levels may reflect severity of disease in patients with PBC. The beneficial effects of UDCA therapy may be explained by lowering serum levels of these two cytokines. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text